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1. Introduction 
 
 
1.1. Graves’ orbitopathy (GO) 
 
1.1.1. Overview 
Clinically evident Graves’ orbitopathy (GO) occurs in about half of the patients 
with Graves’ disease (GD). It is one of the most difficult challenges in the clinical 
practice of ophthalmology. It is usually associated with Graves’ hyperthyroidism, 
however it can occur in Hashimoto’s thyroiditis (HT) and even when there is no 
evident thyroid dysfunction. Pathogenesis of GO, in contrast to Graves’ 
hyperthyroidism, is not fully understood yet. There is a clear pathogenetic link 
between the stimulation of the G protein-coupled thyrotropin receptor (TSH-R) 
by the thyrotropin receptor antibody (TRAb) and hyperthyroidism. TSH-R is also 
considered the central antigen in GO but additional factors cannot be 
disregarded.   
GO has variable clinical presentation. It may cause severe damage to vision 
and the orbital architecture. Potential sight-threatening complications include 
optic neuropathy and severe corneal exposure keratopathy.  
 
1.1.2. Incidence and prevalence 
The incidence rate of GD equals 40 cases in 100,000 people per year, and the 
prevalence is 0,5-2% (Weetman 2003). The prevalence of orbitopathy in GD is 
a matter of definition but clinically it amounts to 25-50% according to Jacobson 
et al. (Jacobson et al. 1985). However CT, MRI or ultrasonography identify 
orbital changes in up to 90% of GD patients (Wiersinga et al. 2002).  
GO, like Graves’ hyperthyroidism, is more common in women. In one study, the 
female: male ratio was 9,3:1 in patients with mild GO, 3,2:1 in those with 
moderate ophthalmopathy, and 1,4:1 in severe ophthalmopathy. Patients with 
GO are older than those with Graves’ hyperthyroidism without GO. 
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GO is in 90-95% concomitant with GD. 3-5% of GO patients suffer from HT, 
further  0,5-5%  demonstrate no thyroid affection. Severe forms affect 3-5% of 
GO patients. Eye disease tends to be more severe in older patients and in 
males (Daumerie 2007). 
 
1.1.3. Pathogenesis 
The pathogenesis of GO is not fully understood yet. Rather than being a 
complication of GD, GO is a concomitant expression of the same underlying 
pathological autoimmune process directed against cross-reactive autoantigens 
in the thyroid and retrobulbar tissues (Wiersinga et al. 2001). Like in GD, both 
genetic and environmental factors play an important role in the development of 
GO (Prabhakar et al. 2003). 
 
1.1.3.1. Genetic susceptibility 
Increased incidence of GD among members of a family indicates that genetics 
might play an important role in determining susceptibility to GD. Twin studies 
show far greater concordance in monozygotic (30-60%) than dizygotic (3-9%) 
twins (Brix et al. 2001). Three principal approaches to investigate the genetic 
complexity of AITD - genome-wide screens, linkage and candidate gene studies 
- contributed to the identification of possible genetic loci and particular genes. 
Several genome screens, using different methods of linkage analysis, showed 
varying degrees of evidence for the linkage between AITD inheritance and 
genetic markers. So far, twin studies concerning GO have not been performed 
and the results of family-based studies are conflicting. The candidate 
susceptibility genes in GD (with and without GO) include both, immune 
modifying genes (e.g. human leukocyte antigen (HLA), cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4), tumor necrosis factor (TNF), immunoglobulin 
heavy chain and interferon-γ (IFN-γ)) and thyroid specific genes (e.g. TSH-R). 
Most likely, these loci interact and their interactions may influence the disease 
phenotype and severity (reviewed by Prabhakar at el. in (Prabhakar et al. 
2003)).  
Up to 79% of the liability to develop GD is attributable to genetic factors, the 
remainder being presumably due to the environmental factors (Brix et al. 2001). 
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1.1.3.2. Possible antigens and antibodies 
Both GD and HT can present with similar findings, including lymphocytic 
infiltration of the thyroid and anti-Tg and anti-TPO autoantibodies in the serum. 
The occurrence of anti-TSH-R autoantibodies (TRAb) is rather exclusively 
associated with the development of the GD phenotype. The clinical course may 
also oscillate between the two disorders. Moreover, both diseases may occur in 
different individuals of the same family, which can lead to the assumption that 
GD and HT have a partially shared pathogenesis (Manji et al. 2006). As the 
majority of patients in the present study have GD, it focuses on this disease.  
The nature of the putative antigen(s) shared by the thyroid and the orbit remains 
elusive, but many elements support the idea that TSH-R represents the culprit 
antigen. 
 
TSH-R:  
TSH-R, expressed on the basolateral membranes of thyroid epithelial cells, is 
the primary regulator of the thyroid cell growth and thyroid hormone synthesis. 
From the time of cloning of the receptor complementary deoxyribonucleic acid 
(cDNA), significant progress has been made in clarifying the structure-function 
relation of the receptor.  It is the 764 amino-acid glycoprotein G protein-coupled 
receptor. The heavily glycosylated and conformed ectodomain is the major site 
of the TSH binding, while seven transmembrane domains and a cytoplasmic tail 
are involved in signal transduction. TSH-R undergoes complex post-
translational processing, involving dimerization, intramolecular cleavage and 
shedding of its ectodomain. Each of these processes may influence the 
antigenicity of TSH-R (reviewed by Prabhakar et al. in (Prabhakar et al. 2003)). 
TRAbs that mimic the TSH actions and stimulate thyroid cells are called TSH-R 
stimulating antibodies (TSAb), whereas those that block the TSH action are 
called TSH-R blocking antibodies (TBAb). Both TBAbs and TSAbs are seen in 
patients with GD (Sugawa et al. 1995).  
 
The TSH-R transcripts have also been demonstrated in orbital fibroblasts and in 
a markedly enhanced number in preadipocytes (cells of the fibroblast lineage 
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that can, under certain culture conditions, differentiate into adipocytes). 
Consensus has now been reached that TSH-R is expressed at the messenger 
ribonucleic acid (mRNA) and protein level in orbital adipose/connective tissue 
specimens of GO patients, but scarcely in that of controls (reviewed by 
Prabhakar et al. in (Prabhakar et al. 2003)). The TSH-R expression is the 
greatest in an early disease and it decreases with time. It is positively correlated 
with the TRAb levels (Boschi et al. 2005). Differentiation into pre-adipocytes 
increases the expression of the TSH-receptor on orbital fibroblasts (Crisp et al. 
1997; Crisp et al. 2000). This would serve as a beacon to T cells, specific for 
TSH-R, and cause homing to orbital tissues.  
There is also clinical evidence that the TSH-R is a crucial autoantigen for GO 
(summarized in (Eckstein et al. 2009)). Higher TRAb levels are associated with 
a significantly higher activity and severity of GO. The persistence of TRAbs in 
patients with a therapy-resistant disease, in comparison to patients with an 
inactive disease, confirms the significance of TRAb in the pathogenesis of GO. 
Even after an anti-inflammatory therapy, TRAb levels and prevalence still 
correlate with the severity and activity of GO. Thus TRAbs seem to both trigger 
and maintain the autoimmune process in the orbits. 
 
IGF-1R 
The IGF-1 receptor is overexpressed by multiple cell types in patients with 
Graves' disease. Antibodies directed at it have been detected in those patients. 
The frequencies of IGF-IR+ B and T cells are substantially increased in patients 
with GD (Smith 2010). 
 
Eye muscle autoantigens 
Eye muscle autoantigens possibly involved in GO include: calsequestrin, 
collagen XIII, flavoprotein, sarcalumenin and a protein called G2s. Most of these 
antigens are localized intracellularly, so they might represent not the primary 
event, but a secondary response, and contribute to maintaining rather than 
triggering the ongoing autoimmune reactions in the orbit (Bednarczuk et al. 
2007). 
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1.1.3.3. Cells and cytokines involved in immune response 
Autoimmunity is a consequence of failure to differentiate self-antigens from non-
self-antigens and it can turn into autoimmune disorders. Defects may appear at 
various stages of the immune response to self-antigens:  central and peripheral 
tolerance mechanisms, apoptosis, T and B cells, regulatory T cells and 
chemokines. In the early phases, two immune processes take place in the 
thyroid. In the first stage, the accumulation of antigen presenting cells in the 
thyroid of susceptible individuals is the most prominent sign of the initiation of 
the autoimmune reaction. This may be due to the inflammatory signals following 
damage or necrosis of the target cells caused by specific environmental factors. 
Alterations in the metabolism or microenvironment of thyroid cells may also be 
the inducing factor. If the immune tolerance is lost, the antigen presenting cells 
present thyroid antigens, interact with and activate T helper lymphocytes. These 
in turn stimulate a cellular and/or humoral response via B lymphocytes 
(Bottazzo et al. 1983). Thyroid cells may also express the major 
histocompatibility complex II (MHCII) molecules and produce various cytokines 
(Ajjan et al. 1997).   
The cell target within the orbit of the autoimmune response remains to be 
defined, but fibroblasts and adipocytes are most likely to be the first involved. A 
diffuse infiltration of lymphocytes, with sparse lymphoid aggregates, is present 
in the extraocular muscle interstitial tissue and in the orbital fatty connective 
tissues of patients with GO (Weetman et al. 1989). The majority of these cells 
are T lymphocytes and macrophages, with sparse B lymphocytes. T helper 
(Th), T suppressive (Ts) and T cytotoxic (Tc) lymphocytes are present, with a 
slight predominance of the latter (Heufelder et al. 1993). Cell-mediated (Th1-
type) immune reactions may predominate in the orbit in the early, inflammatory 
changes of the disease. The proinflammatory cytokines (IFN-γ, interleukin-2 (IL-
2), and TNF-α) produced by these cells, along with IL-1 derived primarily from 
macrophages and fibroblasts, may prove responsible for the stimulation of the 
glycosaminoglycan (GAG) synthesis in orbital fibroblasts, and may function as 
mediators of inflammation in the early disease. The GAGs are water-binding 
proteins and accumulate in both the muscle and connective tissues. The same 
cytokines stimulate the expression of immunomodulatory molecules (HLA-DR, 
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CD54, heat shock protein-72 and CD40) on orbital fibroblasts, potentially 
enhancing the propagation of autoimmune responses within the orbit. Another 
feature of the cytokines relevant to GO is their ability to stimulate the 
proliferation of orbital fibroblasts. In the recovery phase of GO, Th2-type 
lymphocytes (inducing IL-4, IL-5, and IL-10) may play an important role and 
result in the late-stage fibrosis of the extraocular muscles (Prabhakar et al. 
2003).  
 
1.1.3.4. Fibroblasts 
As reviewed by Prabhakar in (Prabhakar et al. 2003), fibroblasts are important 
in the pathogenesis of GO. They are the precursor cells that give rise to more 
specialized components of the connective tissue - myofibroblasts and 
adipocytes. Orbital fibroblasts act as both the target and effector cells in the 
autoimmune process. When activated by the proinflammatory cytokines, orbital 
fibroblasts produce chemokines that initiate lymphocyte recruitment, and 
inducible cyclooxygenase that produces extremely high levels of prostaglandin 
E2. Under such stimulation orbital fibroblasts synthesize high levels of GAGs. 
Orbital fibroblasts include a subpopulation of cells (preadipocytes) which 
differentiate into adipocytes. TSH-R is expressed on the orbital fibroblasts of 
GO patients and its expression increases parallel to adipogenesis (Valyasevi et 
al. 1999). Fibroblasts also display CD40, an important activation molecule. It 
links with CD154 present on T and mast cells, which activates them.  
 
1.1.3.5. Non genetic risk factors  
The risk factors of the occurrence or progression of GO, similar to those leading 
to GD, have been partially identified (Table 1.1.). The list is probably much 
longer and future research should aim at identifying most of the factors. Some 
of the already identified can be prevented but other cannot (Bartalena et al. 
2002). 
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Factor Notes 
Non-preventable (endogenous)  
     Age Incidence peaks in 5th and 7th decades, more 
severe disease stages in older age 
     Gender More severe disease in males 
Preventable (exogenous) 
     Cigarette smoking Association with GO, its prevalence, severity and 
reduced response to treatment 
     Thyroid dysfunction Both hyper- and hypothyroidism may negatively 
affect outcome of GO 
     Radioiodine therapy GO progression/new occurrence in 15% of patients 
after RAI treatment 
     Stressful life events Association with GO 
     Molecular mimicry to     
     infectious agents 
To be defined 
Table 1.1. Risk factors of GO occurrence/progression (Bartalena et al. 2002), modified. 
 
Cigarette smoking greatly increases the risk of GO. The relative risk of smoking 
is 7,7 for GO, but only 1,9 for GD without the eye disease (Prummel et al. 
1993). Smokers tend to have more severe ocular involvement. The severity of 
GO is significantly linked to current rather than lifetime tobacco consumption 
(Prummel et al. 1993; Pfeilschifter et al. 1996). In addition, cigarette smoking 
has been documented to delay the response to the orbital radiotherapy and 
high-dose systemic glucocorticoids (Eckstein et al. 2003). 
 
Dysthyroidism is also associated with the severity of GO (Prummel et al. 1990). 
GO progressively improves after the restoration of euthyroidism (Prummel et al. 
1989). 
 
Initial treatment of GD by RAI leads to death of thyroid cells and release of 
antigens into the circulation. There is a subsequent dramatic increase in the 
levels of TRAbs and in cell-mediated immunoreactivity to TSH-R. During this 
phase, GO exacerbates in 15% of patients (Bartalena et al. 1998). The risk 
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decreases later in the course of the disease (Perros et al. 2005). Smoking and 
stress are associated with an increased risk of developing GD and a reduced 
remission rate after the termination of an antithyroid drug treatment (ATD).  
Molecular mimicry of infectious agents is also believed to break the self-
tolerance and generate the autoimmunity to TSH-R (reviewed in (Prabhakar et 
al. 2003)).  
 
1.1.4. Clinical symptoms and evaluation 
The presentation of GO is highly variable. Usually it is bilateral but it can be 
unilateral too. The onset is rapid or insidious. Photos are used for evaluation of 
the GO development, progression and treatment results (Wiersinga et al. 2006).  
 
1.1.4.1. Upper and lower lid retraction 
Normally the upper lid is located 1-1,5 millimeters below the superior limbus, 
and the lower lid is located at the inferior limbus. Upper lid retraction (Dalrymple 
sign), often with temporal flare and scleral show, is the most common ocular 
sign of GO (Photo 1.1.a,b). Mechanisms for upper lid retraction include 
sympathetic drive of the Müller muscle, fibrosis of the levator muscle, upgaze 
restriction, and proptosis. Lid retraction occurs in both the upper and lower lids 
because of the sympathetically innervated tarsal muscle in both lids. Lid lag on 
downgaze (von Graefe sign) is another important feature of GO. While slowly 
moving the fixation object downwards, the examiner should observe if the eyelid 
lags behind the globe.  
Dalrymple sign, von Graefe sign, lower lid retraction, the width of lid fissure and 
lid closure should be documented for future comparison and observation of the 
course of GO (Photo 1.2.a,b). 
 
 
 
 
 
Photo 1.1.a,b Eyelid retraction. 
a b
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Photo 1.2. Lid assessment: a: width of lid fissure, b: lid lag on downgaze (von Graefe 
sign). 
 
1.1.4.2. Soft tissue inflammation 
Inflammatory changes may be assessed with the help of the Clinical Activity 
Score (CAS). Eyelid erythema, eyelid swelling, conjunctival redness, chemosis 
and inflammation of caruncle or plica are a part of it (Photo 1.3.a,b). Chemosis 
and periorbital edema are due to inflammation, and secondarily to decreased 
venous drainage from the orbit resulting from venous compression  (Bahn et al. 
1993). 
 
 
 
 
 
 
 
 
 
Photo 1.3.a,b. Inflammatory changes. 
 
 
 
b
a b
a
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1.1.4.3. Exophthalmos (proptosis) 
GO is the most frequent cause of uni- or bilateral proptosis in adults. The orbital 
fatty tissue and ocular muscle involvement are closely related to the degree of 
exophthalmos (Nishida et al. 2002) (Photo 1.4.a,b). The degree of proptosis can 
be estimated using the Hertel exophthalmometer. 
 
 
 
 
 
 
 
 
Photo 1.4. Proptosis mostly due to the increase in adipose (a) and muscle tissue 
volume (b).  
 
1.1.4.4. Diplopia 
Swelling and fibrosis, with consecutive contracture of extraocular muscles, may 
result in defective ocular motility in both orbits, even when the disease is 
clinically unilateral (Bahn 2001). Strabismus is common in GO, and it often 
presents as hypotropia or esotropia, since the inferior and medial rectus 
muscles are the most commonly involved extraocular muscles (Edsel et al. 
2005). Some patients have no diplopia either due to symmetric involvement of 
both orbits, amblyopia or because the restriction affects the extremes of gaze 
irrelevant to daily life (Photo 1.5.a,b).  
 
 
 
 
 
 
Photo 1.5.a,b Diplopia. 
 
a b
ba
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Certain tests performed in a sequence determine the presence of fusion, fusion 
vergences and deviations. These are established by cover tests and the prism 
cover test (Photo 1.6.a,b,c).  
 
 
Photo 1.6.a,b,c Motility assessment: a: patient with upgaze deficiency and 
compensatory upward head position, b: ocular excursion measurement with light reflex 
method, c: ocular excursion measurement with Kestenbaum glasses.  
 
The orthoptic assessment includes assessments of head tilt, squint angle if 
present, fusional amplitude, ocular ductions and the field of binocular single 
vision (Esser 1994).  
 
1.1.4.5. Optic nerve compression 
Extraocular muscle dysfunction and enlargement in the orbital apex may result 
from the GAG accumulation, edema and inflammation in the endomysial 
connective tissue, and may cause the optic nerve compression (3-5% of GO 
patients). It may occur with seemingly mild proptosis. For this reason it is 
important to record visual acuity, color vision, fundus assessment and the 
presence or absence of a relative afferent pupillary defect at each visit (Edsel et 
al. 2005). When suspecting the optic nerve compression, the visually evoked 
potentials, CT and MRI scans are helpful in making a diagnosis (Photo 
1.7.a,b,c,d). 
 
a b c
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Photo 1.7. Optic nerve compression: a: MRI: extraocular muscle enlargement in orbital 
apex with straightened optic nerve, b: chemosis and periorbital edema caused primarily 
by decreased venous drainage from orbit, c: decreased visually evoked potentials, d: 
fundus: papilla edema.   
 
1.1.4.6. Ocular surface damage 
Due to the elevated lid aperture, impaired Bell's phenomenon, lagophthalmos, 
reduced tear production and tear film instability, the exposed cornea becomes 
dry and inflamed. The most severe cases may present corneal ulceration. The 
examination includes the basal tear secretion, Rose Bengal and fluorescein 
staining, impression cytology and break-up time (Eckstein et al. 2004; Heinz et 
al. 2004). 
 
 
1.1.5. Activity and severity scores. Course of GO  
A standard assessment of the activity and severity of the disease is a basis for 
a successful treatment. The activity of the disease, rather than its duration, is 
the prime determinant of the outcome of the immunosuppressive treatment in 
GO (Mourits et al. 1997; Terwee et al. 2005). The severity of the disease is the 
key indication for a therapy, while the therapeutic choice depends on the 
inflammatory activity. Therefore, Clinical Activity Score (CAS) (Mourits et al. 
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1997) (Table 1.2.) and the NOSPECS classification (Wiersinga et al. 1991; 
Gerding et al. 2000) (Table 1.3.) were developed - the former in 1997 by 
Mourits et al. and the latter in 1991 by Wiersinga et al. Both are widely used for 
their simplicity, reproducibility and descriptive character. At the first visit only the 
first 7 points of the CAS score can be used for evaluation.  
 
Parameter Score 
Subjective activity signs (in the last 4 weeks) 
Spontaneous orbital pain  1 
Gaze evoked orbital pain  1 
Objective inflammation signs 
Eyelid erythema 1 
Eyelid swelling considered as due to active GO (inflammatory 
phase)  
1 
Conjunctival redness in ≥1 quadrant considered as due to active 
GO (inflammatory phase)  
1 
Chemosis 1 
Caruncle or plica inflammation 1 
Progression signs (in the last 1-3 months) 
≥2mm increase in proptosis  1 
≥8º decrease in ocular excursion in any direction  1 
Decrease of visual acuity equivalent to ≥1 Snellen line 1 
Total score (max.) 10 
Table 1.2. Clinical Activity Score (CAS) parameters.  
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Parameter\Score 0 1 2  3 
Lid retraction no yes   
Soft tissue 
inflammation* 
0 1-4 5-8 >8 
Proptosis  
Site difference 
<17mm 
<1mm 
17-18mm 
1-2mm 
19-21mm 
3-3.5mm 
≥22mm 
≥4mm 
Extraocular muscle 
involvement 
no  >20° upgaze 
>35°abduction 
≤20° upgaze 
≤35°abduction
Corneal defects no yes   
Optic nerve 
compression 
no   yes 
*upper lid edema 0-2, lower lid edema 0-2, conjunctival injection 1, conjunctival 
chemosis 1 
Table 1.3. NOSPECS severity classification.  
 
1.1.6. Natural history                                                                                                                         
In most cases the onset of ophthalmopathy is concomitant with the onset of 
hyperthyroidism, but the eye disease may precede or follow hyperthyroidism 
(Wiersinga et al. 2002). 
The early phase of GO is the progressive deterioration (approximately 4-12 
months) which, after reaching a plateau that lasts months or even years, is then 
followed by a slow but by no means complete improvement. In the Rundle’s 
curve, the line depicting severity does not return to its baseline, in contrast to 
the activity line. The disease reaches inactivity (burnt-out stadium) after 
approximately 18-24 months (Hales et al. 1960). 
A descriptive study by Perros et al. showed the natural course of GO. In 64,5% 
a spontaneous improvement was seen, in 22% the course of the disease was 
stable, while the progressive deterioration was seen in 13,5%. This has 
important implications for managing patients and is critical when assessing the 
effects of different treatments (Perros et al. 1995). 
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1.1.7. Prevention and treatment  
 
1.1.7.1. Prevention of GO 
Primary prevention (i.e. avoiding the occurrence of ophthalmopathy) is not 
feasible yet, but withdrawing from smoking by the GD patients’ relatives might 
be important. In terms of secondary prevention (i.e. avoiding progression of a 
subclinical eye disease into overt and severe ophthalmopathy), apart from not 
smoking, early and accurate control of thyroid dysfunction (both hyperthyroidism 
and hypothyroidism), as well as an early diagnosis and treatment of a mild eye 
disease are also important. In terms of tertiary prevention (i.e. avoiding 
deterioration and complications of an overt disease), an early 
immunosuppressive treatment or orbital decompression as appropriate are 
essential. Withdrawal from smoking may increase the effectiveness of the 
immunosuppressive treatment (Wiersinga et al. 2002). 
 
1.1.7.2. Treatment of GO 
Mild forms of GO are sufficiently treated with symptomatic therapeutic 
interventions or local protective agents (lifting the head of the bed, eye drops, 
dark glasses).  
The anti-inflammatory/immunosuppressive therapy is indicated in patients with 
moderate to severe active GO (CAS≥3 using 7 point score or CAS≥4 using 10 
point score) or progressive GO (high or increasing NOSPECS score) without  
the tendency to spontaneous improvement. In uncertain cases the risk factors, 
i.e. the high/increasing TRAb values and smoking should also be included into 
the dicision-making process. 
Glucocorticoids, orbital radiotherapy or a combination of both are the most 
common immunosuppressants in active GO. 
 
Glucocorticoids are effective on soft tissue, eye muscle involvement of recent 
onset and optic neuropathy. Orbital radiotherapy is particularly effective in 
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improving the eye muscle motility and decreasing the severity of diplopia. In 
very severe cases an immunosuppressive treatment should be considered 
(Bartalena et al. 2008). Very recently new drugs have been evaluated for their 
usefulness in the antiinflammatory treatment of GO. Most promising results 
have been achieved with rituximab (Salvi et al. 2007; Salvi et al. 2008).  
Some GO patients require a surgical treatment. Orbital decompression, 
strabismus surgery and eyelid surgery, following this order, can improve their 
visual functions and appearance. If they do not require orbital decompression, 
then besides inactivity, an interval of 6 months of clinical stability is 
recommended (Eckstein 2010).  
 
1.2. Autoimmune thyroid disease (AITD)  
 
1.2.1. Overview 
Autoimmune thyroid diseases (AITDs) are common polygenic multifactorial 
disorders. Environment contributes importantly to their emergence. The 
autoimmune thyroid diseases include Graves’ disease (GD), Hashimoto’s 
thyroiditis (HT), painless thyroiditis and atrophic thyroiditis. In the present study 
the AITD term refers to GD and HT. GD is a systemic condition which usually 
presents with hyperthyroidism and ophthalmopathy (GO), and occasionally, 
dermopathy and acropachy. GD is due to antibodies to the thyrotropin (TSH) 
receptor (TSH-R) activating the receptor that stimulates the growth of the 
thyroid and excretion of the thyroid hormones (Rapoport et al. 1998). GD is 
characterised by follicular hyperplasia and patchy lymphocytic infiltration of the 
thyroid (Armengol et al. 2001). 
Thyroid autoantibodies against thyroid peroxidase (TPO) and thyroglobulin (Tg) 
in serum, plus varying degrees of thyroid dysfunction are characteristic for HT. It 
is considered to result from an immune response leading to aberrant infiltration 
of autoantigen specific lymphoid cells and destruction of thyroid follicles that 
results in hypothyroidism (Weetman 1996). 
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1.2.2. Diagnosis 
The diagnosis of AITD is made on the basis of a physical examination and 
laboratory tests (thyroxine, triiodothyronine, TSH, TRAb, TPO Ab).  In some 
cases imaging modalities are performed, e.g. thyroid ultrasonography or a 
radioactive iodine uptake test. 
 
1.2.3. Treatment  
Three main thyroid treatment options for patients with GD are the antithyroid 
drug (ATD) treatment, radioiodine therapy (RAI) and surgery. ATD is the first 
choice therapy in Europe. It is usually discontinued after 12-18 months. In case 
of relapse of hyperthyroidism, RAI, thyroidectomy or a different course of the 
ATD therapy are suggested, according to medical indications and the patient’s 
wishes. The management of hyperthyroidism may play a role in the course of 
GO. The ATD therapy and thyroidectomy are associated with a gradual 
decrease in TRAb levels, whereas RAI increases TRAb levels within one year. 
While the ATD therapy and thyroidectomy are rarely associated with 
deterioration of the disease, RAI carries the risk of progression of 
ophthalmopathy in approximately 15% of patients, especially the high-risk 
patients who smoke, have severe hyperthyroidism, high levels of TRAb or a 
preexisting eye disease. However, the risk of the radioiodine-associated 
progression of the orbitopathy can be eliminated by a concomitant treatment 
with middle-dose glucocorticoids (Bartalena et al. 2008).  
In case of hypothyroidism in the course of HT, a substitution therapy with 
levothyroxine is the method of choice.  
 
1.2.4. Risk of relapse of hyperthyroidism 
The recurrence rate of hyperthyroidism after termination of the ATD therapy 
amounts to 60% (Orgiazzi et al. 2002). But if the high TRAb levels persist in 
circulation during ATD therapy, discontinuation of the therapy almost invariably 
leads to the relapse of hyperthyroidism (Schott et al. 2004). Additionally, 
numerous controlled prospective studies performed in many parts of the world, 
with varying iodine intakes, have all confirmed the main initial features related to 
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the subsequent risk of relapse as: smoking, young age, male gender, a goiter 
larger than 40 millilitres, a hypoechogenic and hypervascular gland, presence of 
GO and the severity of hyperthyroidism (Orgiazzi et al. 2002). 
 
1.3. G Protein and signal transduction 
 
1.3.1. Structure and function of G protein, G protein cycle 
Heterotrimeric G proteins (guanine nucleotide-binding proteins) consist of a 
large family of different α-, β- and γ-subunits. Coded by different genes, 5 β-, 13 
γ- and more than 20 α-subunits are currently known. In addition, some of them 
have splice variants or are differentially modified. There are well over a 
thousand possible G protein heterotrimer combinations (Hildebrandt 1997). The 
βγ-subunits should be regarded as functional monomers.  
In a resting state, the guanosine diphosphate (GDP) bound α-subunit is 
associated with βγ-dimer in the inner leaflet of the plasma membrane (Table 
1.4.). After the activation of a coupling receptor, the α-subunit releases GDP in 
exchange for guanosine triphosphate (GTP), and the βγ-subunit dissociates 
from the α-subunit. Both, the free α- and βγ-subunits can direct the activity of a 
variety of effectors. TSH-R is coupled with G protein that activates the adenyl 
cyclase. The α-subunit possesses intrinsic GTPase activity which hydrolyses 
the bound GTP to GDP after the activation. Then the βγ-subunit reassociates 
with the α-subunit, thus ending the activation cycle (Bourne 1997). 
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Table 1.4. G protein cycle discussed above (Weinstein et al. 2001).  
 
1.3.2. Structure and function of Gα-subunit 
The α-subunit is present in all cells of a human body except mature 
spermatozoa. The effects of its stimulation by the seven-transmembrane 
receptor family or various tyrosine kinase receptors include the activation of 
adenyl cyclase that boosts the intracellular cyclic adenosine monophosphate 
(cAMP) concentration. Consequently, the cAMP-dependent signal cascades 
can be either inhibited or activated (Frey 2006).  
  
Types of G proteins: 
• Gαs activates the cAMP-dependent pathway by stimulating the production 
of cAMP from ATP by the enzyme adenyl cyclase.  
• Gαi inhibits the production of cAMP from ATP.  
• Gαq/11 stimulates the membrane-bound phospholipase C beta, which then 
cleaves PIP2 (a minor membrane phosphoinositol) into two second 
messengers, inositol trisphosphate and diacylglycerol.  
• Gα12/13 is involved in the Rho family GTPase signaling and controls cell 
cytoskeleton remodeling, thus regulating cell migration.  
• sometimes Gβγ has active functions. 
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Many of the subunits are expressed ubiquitously, while some have temporal 
and/or differential expression. 
TSH-R acts via Gαs. The regulation of the thyroid cell proliferation in humans is 
dependent on TSH and a number of other growth factors, such as the epithelial 
growth factor, insulin-like growth factor-1, insulin and transforming growth factor 
α. TSH modulates the effects of these growth factors on thyrocytes (Siffert et al. 
1995; Sheu et al. 2005). 
 
Stimulation of Gαs-coupled receptors leads to apoptosis in cells, which 
influences the course and response to the therapy of various tumors and 
inflammatory diseases.   
In addition, different metabolic pathways are regulated by Gαs. Inhibiting the 
expression of Gαs in fibroblasts accelerates their differentiation into adipocytes 
(Wang et al. 1992). 
 
1.3.3. Structure and function of Gβγ-dimers 
Gβ-subunits, including Gβ3, belong to the family of propeller proteins and 
consist of 7 regular domains defined by conserved aminoacid motifs, including 
tryptophan and aspartate (Rosskopf et al. 2003).  
The growth factors mentioned above and TSH act through three major signal 
transduction pathways, including the adenyl cyclase, phospholipase C and 
tyrosine kinases, in order to induce phosphorylation and ultimately switch on the 
thyrocyte proliferation machinery. All the pathways are positively regulated by 
the βγ-subunits of heterotrimeric G proteins (Clapham et al. 1993).   
 
1.3.4. GNAS1 and GNB3 genes. GNAS1 T393C and GNB3 C825T 
polymorphisms  
Polymorphisms are sequence variations in the human genome with the ≥1% 
allele frequency. The exchange of a single nucleotide, commonly referred to as 
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the single nucleotide polymorphism (SNP), accounts for approximately 80% of 
all sequence variants (Sadee et al. 2001). The loss-of-function and gain-of-
function mutations (as well as imprint defects) of the GNAS1 gene lead to 
diverse clinical phenotypes. Because of the fundamental significance of GNAS1 
(GNB3 to lesser extend) for signal transduction, these genomic gene 
modifications are expected to lead to pleiotropic manifestations and are suited 
for prediction of the risks and courses of diseases, as well as responses to and 
side-effects of therapies (drugs, irradiation etc.). Somatic (sporadic) mutations 
in GNAS1 gene, either activating or inactivating, have been implicated in some 
tumors and rare genetic disorders. Mutations which produce constitutively 
active forms of Gsα can lead to endocrine tumors and excess hormone 
secretion (Weinstein et al. 2001).  
Besides mutations in TSH-R, the somatic activating mutations in the Gsα gene 
may cause toxic thyroid adenomas, although less frequently (Duprez et al. 
1998). 
 
GNAS1 T393C 
The GNAS1 human gene is localized on the 20q13.2 chromosome and consists 
of 13 exons, as well as 3 additional upstream promoters that generate 
alternative gene products. Gαs is preferentially expressed from the maternal 
allele in human thyroid glands (genomic imprinting) (Liu et al. 2003). 
A common C393T polymorphism is T to C substitution at the 393 nucleotide 
position. It is located in the exon 5 of the GNAS1 gene encoding the α-subunit 
of heterotrimeric G proteins (numbering according to the cDNA sequence) (Frey 
et al. 2006; Frey 2006). Although this nucleotide exchange is silent and does 
not modify the coded aminoacid (isoleucine), it changes the folding structure of 
the messenger ribonucleic acid (mRNA). Therefore, genotype-dependent 
differences in mRNA due to the altered secondary structure could finally cause 
differences in Gsα mRNA expression (Sheu et al. 2005). 
It can be deduced from ethnic distributions that from the evolutionary 
perspective (relative to Caucasians), “the original state” is the T393 allele. Such 
differences in genotype distribution in ethnic groups generally indicate that the 
associated phenotypes were important for evolution and brought their carriers 
certain advantages (Frey et al. 2006). 
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GNB3 C825T  
The GNB3 human gene is localized on the 12q13 chromosome and is 
composed of 11 exons and 10 introns (Rosskopf et al. 2000). A common C825T 
polymorphism is the C to T change at the 825 nucleotide position. It is located in 
the exon 10 of the GNB3 gene encoding the β3-subunit of heterotrimeric G 
proteins (Siffert et al. 1998). The 825T allele associated with alternative splicing 
of the exon 9 gives rise to a truncated splice variant termed Gβ3-s. This splice 
variant lacking 123 nucleotides gives rise to a functionally active protein missing 
41 aminoacids (Siffert et al. 1999). Another aberrant splicing process was 
identified. It affects the exon 10, giving rise to a splice variant referred to as 
Gβ3-s2 (Rosskopf et al. 2003).   
The GNB3 825T allele is associated  with enhanced G protein activation 
resulting in increased cell proliferation (Siffert et al. 1995). Overexpression of 
Gβ3-s and Gβ3-s2 enhances receptor–mediated GTPγS binding that is 
measure for the Gα GDP/GTP exchange. Therefore, the Gβ3-sγ or Gβ3-s2γ 
dimers may actually interact with the Gα proteins and for instance, destabilize 
the Gα-GDP binding, which could facilitate the receptor-mediated Gα-GDP/GTP 
exchange (Rosskopf et al. 2003). Additionally, Gβ3-s appears to be associated 
with the enhanced immune cell function in humans (Virchow et al. 1998). 
Lindemann et al. (2001) demonstrated that the GNB3 825T allele influenced 
cellular immune responses toward recall antigens and the interleukin-2 
stimulation. Furthermore, lymphocyte chemotaxis and CD4+ T cell counts were 
significantly enhanced in individuals homozygous or heterozygous for the 825T 
allele. The conclusion was that the 825T allele status is predictive of 
immunocompetence and that GNB3 could be a candidate gene in disorders 
associated with an inadequate immune response (Lindemann et al. 2001). 
 
The 825T allele is most frequently found in Blacks - 79%, East Asians show an 
intermediate frequency - 42%, while the lowest frequencies are found in 
Caucasians - 30%. In nonhuman primates, the C alleles are present at the GNB 
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825 locus, suggesting that C is the ancestral state at these positions (Rosskopf 
et al. 2000). 
 
1.3.5. Association between GNAS1 T393C and GNB3 C825T alleles and 
different diseases 
G protein defects can cause a disease in several ways. They may result in the 
production of a G protein that cannot hydrolyze GTP and terminate the signal, 
which leads to increased activity of the downstream effector, even in the 
absence of extracellular stimuli. Decreased production of a normal G protein or 
production of an unstable G protein can reduce the normal response to 
hormonal stimulation. Abnormalities affecting the ability of a G protein to switch 
to the “on” state may result in an increase or decrease in the downstream 
signal. An increase occurs when the defective protein releases GDP and binds 
GTP more rapidly than normally, whereas a decrease, when the protein 
releases GDP more slowly or binds GTP less avidly (Farfel et al. 1999).  
   
The  GNAS1 T393C status is a predictive marker for the clinical outcome of 
colorectal,  bladder and renal cell cancer (Frey et al. 2005; Frey et al. 2005; 
Frey et al. 2006).  
In most studies, the GNB3 825T allele increased the risk for obesity (Siffert et 
al. 1999), hypertension (Schunkert et al. 1998), coronary heart disease (Naber 
et al. 2000), stroke and depression (Zill et al. 2000) in the white population of 
European descent. Furthermore, the  GNB3 825T allele might serve as a 
pharmacogenetic marker to predict the responses to diuretics (Turner et al. 
2001), antidepressants (Zill et al. 2000), endothelin-1 and angiotensin II 
(Wenzel et al. 2002), to name but a few.  
In the thyroid, adenomas showed a statistically significantly lower frequency of 
the 825T allele, which however remains of unknown biological significance 
(Sheu et al. 2005).  
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1.4. Aim of the study 
Till now there are only a few clinical and serological parameters useful for 
prognostic statements in the clinical routine. In the genetic field there are many 
candidate genes and chromosomal regions which underscore the complexity 
and genetic heterogeneity of AITD and GO. However until now no strong 
susceptibility gene which can identify the patients with a higher risk for the 
disease progression or a poor therapy response has been found.  
TSH-R is the central autoantigen for both GD and GO. The TSH-R autoantibody 
levels are associated with the prevalence, severity and response to the 
treatment in the thyroid and orbit disease. However there is no strong genetic 
linkage to the TSH-R gene. Like many other seven-transmembrane receptors, 
TSH-R is G protein-coupled. The TSH binding causes a conformational change 
in TSHR which allows it to act as a guanine nucleotide exchange factor. TSH-R 
activates the G protein by exchanging its bound GDP for GTP. The G protein α-
subunit, together with the bound GTP, can then dissociate from the β and γ 
subunits to further affect intracellular signaling proteins or target functional 
proteins directly, depending on the α subunit type.  
Therefore, the G protein genetic modifications may have significant impact on 
the TSH-R signaling and may affect the course of Graves’ disease. 
The aim of the study was to assess the possible role of the GNAS1 T393C 
polymorphism genotypes of the G protein subunit Gsα, and the GNB3 C825T 
polymorphism genotypes of the G protein subunit Gβ3 in the pathogenesis and 
course of GD and GO.   
For that reason a group of patients with Graves’ orbitopathy, with and without 
the associated thyroid disease, was evaluated for the following parameters: the 
course of orbitopathy (mild/severe), remission or relapse rates of 
hyperthyroidism, levels of the TSH-receptor autoantibodies and thyroid 
parameters. The GNAS1 T393C polymorphism genotypes of the G protein 
subunit Gsα and the GNB3 C825T polymorphism genotypes of the G protein 
subunit Gβ3 were then analysed in these patients and in a control group in 
relation to the above mentioned parameters.  
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The final aim was to find out if these polymorphisms were suitable biomarkers, 
compared to the levels of the TSH-receptor autoantibodies which today are the 
only biomarkers for monitoring the GO/GD patients.   
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2. Patients, materials and methods 
 
This is a case-control association study. 
 
2.1. Patients 
2.1.1. Database patients  
Since November 2000 till January 2008, 916 patients agreed to be included in 
the GO serum sample bank and database in the Center for Ophthalmology of 
the University Hospital in Essen. Their blood samples were taken in different 
stages of the disease. The clinical examination (standard protocol) for the 
database and the blood collection were carried out the same day.  
Patients with infectious diseases (hepatitis B, C, HIV), under an anticoagulant 
treatment or with severe chronic diseases (e.g. tumors) were excluded from the 
database. 
 
2.1.2. DNA donors 
Blood samples from 359 patients of the GO database of Caucasian origin were 
available.  
 
2.1.3. Inclusion criteria 
Our patients met the following inclusion criteria: 
The diagnosis of GO and AITD type Graves’ disease = with hyperthyroidism 
(n=325) 
• typical symptoms of GO 
• initially, or at least once over the course of the disease, pathological 
TRAb levels and suppressed TSH; 
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For classifying GO (n=359) 
• initial presentation within 6 months after the GO onset 
• an ophthalmologic assessment 11-14 months after the GO onset; 
 
For classifying the course of hyperthyroidism (GD) (n=272) 
• an initial treatment of hyperthyroidism with the ATD treatment for one    
  year 
• follow-up for at least 24 months. 
 
The GD remission was defined as a period of at least 12 months of 
euthyroidism after the termination of the ATD therapy (TSH and thyroid 
hormones within a normal range). When GD relapsed, patients were referred for 
a radioiodine therapy, thyroidectomy or a second one-year cycle of the ATD 
therapy, according to the medical indications and a patient’s individual 
preferences. A definitive treatment (thyroidectomy or radioiodine therapy) of the 
thyroid was performed in case of relapse of GD or uncontrolled hyperthyroidism 
under the high-dose ATD therapy. 
 
The missing information regarding laboratory values and a prior treatment was 
obtained from either an endocrinologist or a general practitioner. 
 
2.1.4. Standard protocol for GO assessment 
 
1. History was taken using a standard form: 
a. endocrinological history 
• first symptoms and first diagnosis of thyroid dysfunction 
• previous treatment of thyroid hyperfunction 
• present treatment of thyroid hyperfunction 
• name and address of endocrinologist or general practitioner; 
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b. ophthalmological history 
• first symptoms and first diagnosis of GO 
• previous treatment of GO 
• present treatment of GO 
• name and address of ophthalmologist 
• present complaints (spontaneous and gaze evoked orbital pain; 
 decrease in eye motility, visual acuity and proptosis increase in 
 last 3 months); 
c. general history 
• height and weight 
• other diseases and treatment 
• tobacco smoking. 
 
2. A standard GO clinical assessment included the following:  
a. Visual acuity  
b. A lid function (significant lid retraction was defined as 1mm or more 
scleral show or a side difference of ≥1mm) 
c. Intraocular pressure - measured with the Goldmann tonometer in the 
primary position and upgaze 
d. Proptosis (significant proptosis was the proptosis of 17mm or more and 
the ≥1mm side difference)  
e. The eye position and motility (significant impairment was defined if 
monocular excursions were reduced by ≥5°) 
f. Presence or absence of corneal defects 
g. Presence or absence of the optic nerve compression 
h. CAS 
i. NOSPECS 
 
Concerning GO, follow-up visits were performed every 3 months until the 
disease had been inactive for at least 6 months, or the surgical rehabilitation of 
the pathology was completed. Clinical activity was assessed according to the 10 
point score (CAS) of Mourits et al. (Mourits et al. 1997).  
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During the follow-up, all patients with ≥4 CAS values (in cases of severe 
impairment of motiltiy also when CAS=3)  were offered a systemic steroid 
treatment. The regimen for a mild and moderate disease began with 1,5 
milligrams of fluorocortolone orally per kilogram of body weight, tapered by 10 
milligrams every 4 days. In severe cases, intravenous steroids were given every 
other day for 5 days, a single dose of 500 milligrams of prednisolone 
hemisuccinate per day. This scheme was followed by the oral regime as in the 
mild disease.  
 
Orbital irradiation was performed if patients suffered from the impaired ocular 
motility or if the clinical activity increased after the steroid withdrawal (regimen: 
total dosage usually 12-20 Gy). The severity of orbitopathy was recorded  
applying the modified NOSPECS classification as described before (Eckstein et 
al. 2006). 11 to 14 months after the onset of GO, patients were grouped 
according to the severity of the disease. The mild course was defined as CAS 
<4 (almost an inactive disease) and/or NOSPECS <5 (mild signs of GO), 
whereas the severe course, as CAS >4 (still an active disease) and/or 
NOSPECS >5 (marked signs of GO) (Table 2.1.). 
 
Course of GO NOSPECS CAS 
Mild 0-4 0-3 
Severe 5-14 4-10 
Table 2.1. Classification of GO course in two groups according to CAS and NOSPECS 
scores (if either CAS or NOSPECS belonged to severe group, the course was 
classified as such). 
 
2.1.5. Healthy control group 
 820 healthy blood donors for the GNAS1 T393C polymorphism and 1855 
healthy blood donors for the GNB3 C825T polymorphism assay were recruited 
at the Department of Transfusion Medicine of the University Hospital in Essen. 
They were Caucasians of both genders, 18-65 years old, with weight of over 50 
kilograms, and under no medication treatment or drug abuse. All samples were 
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collected randomly from the blood donors. These control groups were 
previously characterized in detail (Siffert et al. 1999). 
 
2.2. Materials 
The whole venous blood was obtained from each patient with the help of 
“Butterflies” (Dispomed Ecoflo), the brown serum and red EDTA tubes 
(Sarstedt). The serum was analyzed for TSH, free thyroxine, free 
triiodothyronine and the TRAb values. The whole blood was used for the DNA 
isolation. Afterwards, the samples were stored in -80°C. 
 
 
2.3. Experimental procedures 
2.3.1. DNA isolation 
QIAamp® DNA Blood Mini Kit (Qiagen, Hilden, Germany) was used for DNA 
purification from the whole blood EDTA samples. 20μl Proteinase K, 200μl 
blood sample and 200μl Buffer AL were added to a microcentrifuge tube, mixed 
by pulse-vortexing for 15 seconds and incubated at 56°C for 10 minutes. Then, 
200μl 100% ethanol was added and the sample was again mixed by pulse-
vortexing for 15 seconds. Afterwards, the mixture was carefully applied to the 
QIAamp Spin Column and centrifuged at 8000rpm for 1 minute. The spin 
column was in the next step placed in a clean collection tube, and the tube 
containing the filtrate was discarded. 500μl Buffer AW1 was added and 
centrifuged at 8000rpm for 1 min. The spin column was placed in a clean 
collection tube, and the tube with the filtrate was discarded. The same 
procedure was repeated with 500μl Buffer AW2 with centrifugation at 14000rpm 
for 3 minutes. Then 200μl Buffer AE was added, incubated at room temperature 
for 1 min and centrifuged at 8000rpm for 1 minute. The samples containing the 
isolated DNA were stored in -20°.  
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2.3.2. Polymerase Chain Reaction (PCR) 
Appropriate volumes of the Taq PCR MasterMix (Eppendorf, Germany) (Table 
2.2.), primers (Invitrogen, Germany) (Table 2.3.) and aqua pro iniectionae were 
dispensed into the PCR tube and mixed, avoiding formation of foam. Then, the 
template DNA was added (Table 2.4.). As PCR is a sensitive technique capable 
of amplifying even trace amounts of DNA, the components (excluding template 
DNA) were mixed in DNA-free environment using aerosol-resistant barrier tips, 
to avoid contamination. Template DNA was added afterwards in a separate 
room. In the next step, the PCR program was started on the thermal cycler. 
After 5-minute denaturation at 94°C, 38 cycles of DNA amplification were 
performed for 30 seconds at 94°C (denaturation), 40 seconds at 64°C 
(annealing) and 45 seconds at 72°C  (extension).    
 
Component Concentration 
Taq DNA Polymerase 1,25 U 
KCl 50mM 
Tris-HCl 30mM 
Mg2+  1,5mM 
Igepal-CA630 0,1% 
Each dNTP 200μM 
Table 2.2. Components of Eppendorf MasterMix (2,5x) and their final concentrations in 
PCR. 
 
 GNAS1 T393C GNB3 C825T 
Forward 
primer 
(sense) 
FOK2  
5’-TGTGGCCGCCATGAGCAA-3’ 
BSE1  
5’-GCTGCCCAGGTCTGATCCC-
3’ 
Reverse 
primer 
(antisense) 
FOK1  
5’-
TAAGGCCACACAAGTCGGGGT-3’ 
BSE2  
5’-
TGGGGAGGGTCCTTCCAGC-3’ 
Table 2.3. Names and sequences of oligonucleotide primers used for PCR. 
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Components GNAS1 T393C GNB3 C825T 
Eppendorf MasterMix 
(2,5x) 
13μl 12μl 
Forward primer 1μl 2μl 
Reverse primer 1μl 2μl 
Aqua pro iniectionae 15μl 14μl 
Template DNA 2μl 2μl 
Table 2.4. Components used for PCR. 
 
2.3.3. Restriction and visualisation of final products 
In the presence of a buffer (NEB and MBI Fermentas, St.Leon-Rot) and aqua 
pro iniectionae, the PCR products were digested using a restriction enzyme 
(NEB and MBI Fermentas, St.Leon-Rot) (Tables 2.5. and 2.6.) at 56°C for 3 
hours (GNAS1 T393C) and 1,5 hour (GNB3 C825T) respectively. The final 
products were separated by electrophoresis on a 2,5% agarose gel, and 
visualized by ethidium bromide staining (Sigma, Deisenhofen, Germany)  under 
ultraviolet light. Photos were taken and analysed.  
 
Components GNAS1 T393C GNB3 C825T 
Restriction enzyme 0,1μl 0,2μl 
Puffer Y Tango 2,5μl 3μl 
Aqua pro iniectionae 17,4μl 16,8μl 
Table 2.5. Restriction components. 
 
 
 GNAS1 T393C GNB3 C825T 
Restriction 
enzyme 
BSeGI 5’-NNCATCC-3’ BSED1 5’-CCNNGG-3’ 
Table 2.6. Names and sequences of restriction enzymes.  
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The CC sequence is recognized and cut by restriction enzymes. Therefore it is 
assumed that in GNAS1 T393 the unrestricted products (145bp) represent the 
TT genotype, and the completely restricted products (78 and 77bp) represent 
the CC genotype. The presence of both the unrestricted and restricted products 
indicates the heterozygous TC genotype (Photo 2.1.). 
  
 
 
 
Photo 2.1. Photograph of agarose gel representing electrophoresis outcome of 
restricted and unrestricted PCR products of GNAS1 T393C gene. Handwritten 
numerals indicate ID numbers of patient samples. 
 
Analogically, in GNB3 C825T, the unrestricted products (269bp) represent the 
TT genotype, and the completely restricted (153 and 116bp), the CC genotype. 
The presence of both unrestricted and restricted products indicates the 
heterozygous TC genotype (Photo 2.2.). 
 
TT  TT     λ   TC  TC  TC   TC  TC  TT  CC 
 145 bp 
  77/78 bp
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Photo 2.2. Photograph of agarose gel representing electrophoresis outcome of 
restricted and unrestricted PCR products of GNB3 C825T gene. Handwritten numerals 
indicate ID numbers of patient samples. 
 
2.3.4. Thyrotropin receptor antibody (TRAb) assay 
TRAb were measured using the second generation TSH binding inhibitory (TBII) 
assay based on the TSH-R human recombinant (Costagliola et al. 1999) (TRAK 
human LIA®, B.R.A.H.M.S AG, Hennigsdorf/Berlin, Germany). This assay is 
calibrated in international units (IU) based on the standard WHO reference, 
MRC 90/672. As described in more detail by Schott et al. the 50% inhibition of 
tracer binding corresponds to 7-8 IU/l. Values ≥1.5 IU/l (about 10% of tracer 
binding) were regarded as positive, values between 1 and 1.5 IU/l as borderline 
and values <1.0 IU/l as negative (Schott et al. 2000). The TRAb values were 
evaluated at the GD onset, 6 months after the beginning of the ATD therapy, as 
well as 6 months after the GO onset.  
 
  λ      TC TC  TT TT CC TC  TC  CC TT 
269 bp 
  153 bp 
  116 bp 
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2.4. Statistic analysis 
Group comparisons were performed with the chi-square test for categorical 
variables, and with the t-test for normally distributed continuous variables. The 
Mann-Whitney or Kruskal-Wallis tests were used for non-normally distributed 
continuous variables. Stepwise logistic regression was carried out in order to 
establish whether and to what extent the course of hyperthyroidism was 
influenced by the following parameters: the GNAS1 genotype, TRAb levels 6 
months after the beginning of the ATD treatment, the course of GO, age, 
gender, and smoking. The ROC plot analysis was performed in order to define 
the TRAb cut-off levels for the prediction of the GO and GD courses. 
For all the tests, p values less than 0,05 were considered significant. Analyses 
were performed with the GraphPad Prism version 3.00 for Windows (GraphPad 
Software, San Diego, CA, USA), SPSS 15.0 (SPSS, Chicago, IL, USA) and 
SAS 9.1 (SAS Institute Inc., Cary, NC, USA).  
 
2.5. Medical Ethics Committee approval  
Written consent was obtained from all the participants. The study was approved 
by the Medical Ethics Committee of the University of Essen. 
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3. Results 
 
 
3.1. Patient characteristics 
 
3.1.1. Age at GO onset 
The incidence was the highest in 30-60 years old patients (Fig. 3.1.). The 
median age was 47,9 years (15,7-83,0). 
 
 
Fig. 3.1. Age of patients at GO onset. 
 
3.1.2. Gender distribution 
There were 307 (85,5%) females and 52 (14,5%) males. The female: male ratio 
equaled 5,9:1. 
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3.1.3. Smoking  
There were slightly more smokers than nonsmokers (188 vs. 171; 52,4% vs. 
47,6%). 
 
3.1.4. Duration of hyperthyroidism at GO onset 
On average Graves’ hyperthyroidism was diagnosed 2 months (median) before 
the onset of GO. However, this relation varied ranging from 30,4 years before to 
3 years after the onset of GO. The majority (67,2%) of patients manifested GO 
simultaneously or within 6 months before or after the onset of the thyroid 
disease. GO was rarely present (1,5%) earlier than 6 months before GD onset. 
In contrary, the GO onset later than 6 months after the GD onset was more 
frequent (31,3%) (Fig. 3.2.).  
 
 
Fig. 3.2. Time relation between GO and GD onsets. 
 
3.1.5. Frequency of GO signs  
When classifying the course of GO, 11 to 14 months after its onset, the 
prevalence of the signs of GO was evaluated. The most common GO sign was 
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the soft tissue inflammation, followed by proptosis. The least frequent sign was 
the optic nerve compression (Fig. 3.3.). The mean (SD) CAS and NOSPECS 
values equaled 3,1 (2,3) and 5,0 (2,9).  
 
 
 
 
Fig. 3.3. Frequency of particular GO signs 11 to 14 months after GO onset.  
 
3.1.6. Thyroid status at GO onset 
The majority of 359 patients, 152 (42,3%), presented the thyroid hyperfunction 
simultaneously with GO, or up to 6 months prior or after GO. Out of 144 (40,1%) 
patients in whom the thyroid hyperfunction preceded the eye pathology more 
than 6 months, 60 patients had undergone the definitive thyroid treatment 
before the GO manifestation. In 29 (8,1%) patients, the thyroid disease 
occurred more than 6 months after the onset of GO. 14 (3,9%) patients 
presented Hashimoto’s thyroiditis and 20 (5,6%) were euthyroid during the 
whole follow-up.   
 
55,3
84,9
74,9
48,9
16,5
6,1
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Upper lid retraction
Soft tissue inflammation
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Corneal defects
Optic nerve compression
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3.1.7. TRAb levels 6 months after onset of GO in relevance to thyroid 
function 
The TRAb values 6 months after the GO onset differed in relevance to the type 
of the thyroid involvement (p<0,0001): GD vs. euthyroidism (p<0,001) and GD 
vs. HT(p<0,05). There was no significant difference of the TRAb values in the 
groups with euthyroidism and HT(p>0,05) (Fig. 3.4.). 
 
 
Fig. 3.4. TRAb levels (IU/l) in relevance to thyroid function. 
 
The TRAb values in relevance to the course of GO and hyperthyroidism are 
presented in the chapters 3.4.5. and 3.5.8. 
 
3.1.8. Family history of AITD and other autoimmune diseases  
13,1% of GO patients confirmed other autoimmune diseases (diabetes mellitus 
type 1, vitiligo, rheumatoid arthritis, neurodermitis, Crohn disease, myasthenia 
gravis, and autoimmune gastritis). The family history of AITD was positive in 
29,5% of the patients (Fig. 3.5.). 
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Fig. 3.5. Frequency of family history of AITD and concomitant autoimmune diseases. 
 
3.2. GNAS1 and GNB3 genotype GD versus controls 
Genotype distribution was compatible with the Hardy-Weinberg equilibrium. 
 
There was no significant difference of the GNAS1 and GNB3 SNP genotypes 
(p=0,86 and 0,67) and allele distribution (p=0,94 and 0,41) between the control 
group and patients with hyperthyroidism (Tables 3.1. and 3.2.).   
 
Sample n* CC n (%) CT n (%) TT n (%) Cn Tn fT (%) 
Controls 820 235 (28.6) 403 (49.2) 182 (22.2) 869 771 47.0 
GD patients 268 78 (29,1) 127 (47,4) 63 (23,5) 283 253 47,2 
Table 3.1. GNAS1 T393C genotype and T allele frequency (fT) in patients with GD and 
controls. n=4 patients could not be genotyped due to technical difficulties. 
 
 
Sample n CC n (%) CT n (%) TT n (%) Cn Tn fT (%)
Controls 1859 906 (48.7) 791 (42.6) 162 (8.7) 2603 1115 30.0 
GD patients 269 139  (51,7) 108 (40,1) 22 (8,2) 286 152 28,3 
Table 3.2. GNB3 C825T genotype and T allele frequency (fT) in patients with GD and 
controls. n=3 patients could not be genotyped due to technical difficulties. 
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3.3. GNAS1 and GNB3 genotype GO versus controls 
Genotype distribution was compatible with the Hardy-Weinberg equilibrium. 
 
There was no significant difference of the GNAS1 T393C and GNB3 C825T 
genotypes (p=1,0 and 0,95) and allele distribution (p=0,84 and 0,95) between 
the controls and patients with GO (Tables 3.3. and 3.4.  and Fig. 3.6.).   
 
Sample n CC n (%) CT n (%) TT n (%) Cn Tn fT (%) 
Controls 820 235 (28,6) 403 (49,2) 182 (22,2) 869 771 47,0 
GO patients 354 100 (28,2) 172 (48,6) 82 (23,2) 372 336 47,5 
Table 3.3. GNAS1 T393C genotype and T allele frequency (fT) in patients with GO and 
controls. n=5 samples could not be genotyped due to technical difficulties. 
 
 
Sample n CC n (%) CT n (%) TT n (%) Cn Tn fT (%)
Controls 1859 906 (48,7) 791 (42,6) 162 (8,7) 2603 1115 30,0 
GO patients 355 175 (49,3) 148 (41,7) 32 (9.0) 498 212 29,9 
Table 3.4. GNB3 C825T genotype and T allele frequency (fT) in patients with GO and 
controls. n=4 patients could not be genotyped due to technical difficulties. 
 
 
Fig. 3.6. Genotype distribution of GNAS1 T393C and GNB3 C825T SNPs in patients 
with GO and controls.  
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3.4. GNAS1 and GNB3 genotype, nongenetic factors  and course of GO 
 
3.4.1. Course of GO 
359 patients were followed up for median (range) 25 months (11 to 235). After a 
12-month follow-up (range 11 to 14 months), the clinical course was classified 
as mild in 152 patients (42,3%), while 207 patients (57,7%) showed a severe 
course. Oral or intravenous steroids were administered to 300 patients (83,6%), 
while 190 (53,0%) received a retrobulbar irradiation therapy.  
 
3.4.2. Overview of all factors with possible influence on course of GO 
Table 3.5. shows that the GNAS1 T393C and GNB3 C825T genotypes have no 
influence on the course of GO. Many clinical parameters were identified as risk 
factors for the course of GO: age, gender, thyroid volume and antibodies, as 
well as smoking.  
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 Course of GO  
Parameter All mild severe 
 
P 
n(%) 359 152(42,3) 207(57,7)  
GNAS1 T393C 
genotypes CC/TC/TT 
100/172/82 
 
37/82/30 63/90/52 0,118 
 
GNAS1 T393C fT* 47,5 47,6 47,3 0,930 
GNB3 C825T genotypes 
CC/TC/TT 
175/148/32 
 
73/63/13 102/85/19 0,975  
GNB3 C825T fT  29,9 29,9 29,9 1,0 
Gender (female/male) 307/52 136/16 171/36 0,068 
Age at GO onset (years) 47,9(11,9) 44,2(11,7) 50,7(11,2) <0,0001 
GD duration at GO onset 
(months) 
2,0(-36 to 364) 1,0(-26 to 334) 3,0(-36 to 364) 0,091 
Smoking 
(smoker/nonsmoker) 
188/171 
 
60/92 128/79 <0,0001 
Thyroid volume (ml) 20,0(2,1-
135,0) 
17,0(6,5-
135,0) 
26,0(2,1-
105,0) 
<0,0001 
TRAb at GD onset (IU/I) 9,7(0,0-40,0) 6,5(0,4-40,0) 14,1(0,0-40,0) 0,013 
TRAb 6 months after GD 
onset (IU/I) 
5,0(0,0-40,0) 2,6(0,0-40,0) 6,8(0,0-40,0) 0,001 
TRAb 6 months after GO 
onset (IU/I) 
5,7(0,0-40,0) 3,2(0,0-40,0) 7,5(0,0-40,0) <0,0001 
Thyroid status at last 
control 
(remission/relapse) 
62/210 
 
36/62 26/148 <0,0001 
*fT – T allele frequency 
Table 3.5. Descriptive statistics of study patients sorted by course of GO. Categorical 
variables are given as numbers, continuous variables as means (SD) and medians 
(min-max). Due to technical problems n=5 samples could not be genotyped for GNAS1 
T393C SNP and n=4 samples could not be genotyped for GNB3 C825T SNP.  
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3.4.3. Course of GO and GNAS1 and GNB3 genotype 
There were no significant differences of the genotype and allele distributions in 
the GNAS1 T393C and GNB3 C825T SNPs (p=0,12; 0,93; 0,98 and 1,0, 
respectively) between the patients with the mild and severe GO (Fig. 3.7.).   
 
 
Fig. 3.7. Genotype distribution of GNAS1 T393C and GNB3 C825T SNPs sorted by 
course of GO. 
 
3.4.4. Relation between course of GO and gender 
307 females (136 with a mild course, 171 with a severe course) and 52 males 
(16 with a mild course, 36 with a severe course) were included in the study. The 
female: male ratio equaled 8,5:1 in the patients with the mild course and 4,75:1 
in the patients with the severe course of GO. A tendency to develop more 
severe GO symptoms was found in men (p=0,068) (Table 3.5.). 
 
3.4.5. Relation between course of GO and age at GO onset  
The course of GO depended on the median age of the patients at the disease 
onset (p<0,0001) (Fig. 3.8.). The older the patient, the more severe the GO 
symptoms. The CAS and NOSPECS values illustrate the associations: for CAS 
p<0,0001, r=0,239; for NOSPECS p<0,0001, r=0,334. 
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Fig. 3.8. Relation between age of patients at GO onset and disease severity. 
 
As far as particular NOSPECS symptoms are concerned, there was a 
significant difference in the mean age of the patients relative to the presence of: 
the soft tissue inflammation (44,1±11,6 and 48,6±11,8 respectively; p=0,009), 
extraocular muscle involvement (44,0±11,2 and 52,0±11,2 respectively; 
p<0,0001), corneal defects (47,2±11,7 and 51,4±12,0 respectively; p=0,013) 
and the optic nerve compression (47,5±8,5 and 53,5±10,4 respectively; 
p<0,0001). No significant difference regarding the upper lid retraction was 
found. 
 
3.4.6. Relation between course of GO and GD duration  
There was no significant difference in the median duration of the thyroid disease 
at the GO onset in relation to the course of GO (p=0,091). 
 
3.4.7. Relation between course of GO and smoking  
There were more smokers (60 with the mild and 128 with severe course, 39,5% 
and 61,8% respectively) than nonsmokers (92 with the mild and 79 with severe 
course, 60,5% and 38,2% respectively) (p<0,0001). 
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Smoking increased the risk for the severe course of GO (OR=2,49 [1,62-3,82]; 
p<0,0001).  
No significant differences in TRAb levels between smokers and nonsmokers 
were found at the GD onset, 6 months after the GD onset and 6 months after 
the GO onset (p=0,307; 0,181 and 0,092, respectively). 
 
3.4.8. Relation between course of GO and thyroid volume 
As shown in the Table 3.5. and Fig. 3.9., there was a significant difference of 
the thyroid volume in the patients with the mild and severe courses of GO 
(p<0,0001). The thyroid volume was also related to the TRAb values 6 months 
after the onset of GO (p<0,0001, r=0,302). 
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Fig. 3.9. Thyroid volume and course of GO. 
 
3.4.9. Relation between course of GO and TRAb levels  
There was a significant difference of the median TRAb values 6 months after 
the GO onset in the patients with the mild and severe courses of GO, p<0,0001 
(Fig. 3.10.). 
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Fig. 3.10. TRAb levels 6 months after GO onset and course of GO. 
 
In order to predict the course of GO the ROC plot analysis was performed which 
defined the cut-off levels of the TRAb values 6 months after the GO onset 
(Table 3.6. and Fig. 3.11.).  
 
 
 TRAb cut-off 
(IU/l) 
Sensitivity 
(%) 
Positive 
predictive 
value 
Odds 
ratio(95%CI) 
mild GO <3,0 48 0,65 5,4(3,4-8,8) 
severe GO >11,2 51 0,75 3,5(2,1-5,8) 
Table 3.6. TRAb cut-off levels for prediction of course of GO at specificity level of 90%. 
 
55 
 
1 - specificity
1,00,80,60,40,20,0
se
ns
iti
vi
ty
1,0
0,8
0,6
0,4
0,2
0,0
 
Fig. 3.11. ROC curve for TRAb levels 6 months after GO onset in patients with severe 
course of GO. 
 
 
3.4.10. Relation between course of GO and course of thyroid disease 
This topic will be dealt with in the chapter 3.5.9.  
 
3.5. GNAS1 and GNB3 genotype, nongenetic factors and course of 
hyperthyroidism 
 
3.5.1. Course of thyroid disease 
The course of hyperthyroidism could be determined in 272 patients. They were 
followed up for median 35 months (24-559). By the end of the observation 
period the patients had either received a definitive thyroid treatment or 
completed a follow-up period of 12 months after the termination of the ATD 
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therapy. Among the relapsing patients, 120 (59,4%) underwent thyroidectomy, 
51 (25,3%) received a radioiodine treatment and 31 (15,3%) both the 
treatments. Further 8 patients who relapsed were not assigned the definitive 
thyroid treatment by then. 62 (23,5%) patients remained in remission. 
The course of hyperthyroidism could not be classified in 53 patients, as they 
were still under the ATD therapy or had not completed the follow-up period of 
12 months after the cessation of ATD. 
 
3.5.2. Overview of all factors with possible influence on course of thyroid 
disease 
Table 3.7. presents an overview of the candidate factors that could influence the 
course of hyperthyroidism. The strongest association was found to the level of 
the TSH-R autoantibodies. The higher the antibody levels, the significantly 
poorer the prognosis for the remission of hyperthyroidism. The GNAS1 
genotype was also associated with the course of hyperthyroidsim. The TT 
genotype carries a higher risk of relapse. The presence of at least one C allele 
means a better prognosis. Whereas older age and higher thyroid volume were 
associated with a poorer prognosis. Smoking and gender were not associated 
with a higher risk of the hyperthyroidism relapse. 
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Thyroid status at last control  
Parameter 
 
All remission relapse 
 
P 
n(%) 272 62(22,8) 210(77,2)   
GNAS1 T393C 
genotypes CC/TC/TT  
78/127/63 
 
15/39/8 63/88/55 0,013 
GNAS1 T393C 
genotypes 
CC+CT/TT 
205/63 54/8 151/55 0,025 
GNAS1 T393C fT* 47,2 44,4 48,1 0,47 
GNB3 C825T 
genotypes CC/TC/TT 
139/108/22 
 
34/24/4 105/84/18 0,782  
GNB3 C825T fT  28,3 25,8 29,0 0,490 
Gender 
(female/male) 
238/34 57/5 181/29 0,229 
Smoking 
(smoker/nonsmoker) 
146/126 29/33 117/93 0,215 
Age at GO onset 
(years) 
48,5(19,8-
78,3) 
45,9(24,1-
78,3) 
49,1(19,8-
74,1) 
0,023 
Thyroid volume (ml) 25,0(8,0-
135,0) 
19,5(8,5-57,0) 28,5(8,0-
135,0) 
0,031 
TRAb at GD onset 
(IU/I) 
12,9(0,0-40,0) 5,4(1,0-32,8) 20,5(0-40,0) <0,0001 
TRAb 6 months after 
GD onset (IU/I) 
8,0(0,01-40,0) 3,4(0,01-24,0) 11,4(0,5-40,0) <0,0001 
Course of GO 
(mild/severe) 
272 36/26 62/148 <0,0001 
*fT – T allele frequency 
Table 3.7. Descriptive  statistics of study patients sorted by thyroid status at last 
control. Categorical variables are given as numbers, continuous variables as means 
(SD) and medians (min-max). Due to technical problems n=4 samples could not be 
genotyped for GNAS1 T393C SNP, n=3 samples could not be genotyped for GNB3 
C825T SNP.  
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3.5.3. Course of hyperthyroidism and GNAS1 and GNB3 genotype 
Genotype distribution was compatible with the Hardy-Weinberg equilibrium. 
 
A statistical difference was found in the GNAS1 genotype between the 
remission and relapse groups (p=0,013) (Fig. 3.12.). However, the allele 
distribution (p=0,47) did not reach the significance level. 
The homozygous TT carriers showed a significantly increased risk (p=0,025) of 
the hyperthyroidism relapse (odds ratio 2,5; 95% confidence interval 1,1-5,5).   
The relapse rate in the homozygous TT carriers reached 87,3%, as opposed to 
73,7% in the carriers of at least one C allele (CT/CC). The absence of the C 
allele was also significantly (p=0,02) associated with the higher TRAb levels 6 
months after the initiation of the ATD therapy (10,0 IU/l in homozygous TT 
carriers vs 5,6 IU/l in CC/CT carriers) (Fig. 3.13.). The GNAS1 status was not 
related to the thyroid volume (CT/CC allele vs TT allele carriers p=0,106). 
 
 
Fig. 3.12. Genotype distribution of GNAS1 T393C and GNB3 C825T SNPs sorted by 
course of GD.  
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Fig. 3.13. TRAb levels (IU/l) 6 months after initiation of ATD therapy sorted by C allele 
of  GNAS1 T393C genotype.  
 
There was no statistical difference in the GNB3 C825T genotype between the 
remission and relapse group for either the genotype (p=0,782) or allele 
distribution (p=0,49).   
 
3.5.4. Relation between course of hyperthyroidism and gender 
238 females (57 in the remission and 181 in the relapse group) and 34 males (5 
in the remission, 29 in the relapse group) were included in the study. The 
female: male ratio equaled 11,4:1 in the remission and 6,2:1 in the relapse 
patients. No significant connection between their gender and course of 
hyperthyroidism was found (p=0,229). 
 
3.5.5. Relation between course of hyperthyroidism and age 
There was a significant difference (p=0,023) in the median age of the patients in 
relevance to the course of hyperthyroidism. The older the patient, the higher the 
risk of the hyperthyroidism relapse (median age 49,1 vs 45,9 years in the 
remission group).  
60 
 
3.5.6. Relation between course of hyperthyroidism and smoking 
There were 46,8% smokers in the remission and 55,7% in the relapse group. 
No significant connection between smoking and the course of hyperthyroidism 
was demonstrated (p=0,215). 
 
3.5.7. Relation between course of hyperthyroidism and thyroid volume 
There was a significant difference in the thyroid volume relative to the course of 
hyperthyroidism (p=0,031). The thyroid volume was also associated with the 
TRAb values at the diagnosis of Graves’ hyperthyroidism (p<0,0001, r=0,318) 
and 6 months afterwards (p<0,0001, r=0,380). 
 
3.5.8. Relation between course of hyperthyroidism and TRAb levels  
The TRAb levels at the onset of hyperthyroidism and 6 months afterwards 
differed significantly between the remission and relapse groups (Fig. 3.14). 
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Fig. 3.14. TRAb levels (IU/l) at GD onset and 6 months afterwards, sorted by course of 
GD, for each p<0,0001. Dotted line indicates positive (>1,5 IU/l) TRAb levels, grey 
zone ranges between 1,0 IU/l - 1,5 IU/l.  
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In order to predict the course of hyperthyroidism the ROC plot analysis was 
performed which defined the cut-off levels of the TRAb values 6 months after 
the GD onset (Table 3.8. and Fig. 3.15.).  
 
 
 TRAb cut-off 
(IU/l) 
Sensitivity 
(%) 
Positive 
predictive 
value 
Odds 
ratio(95%CI) 
remission  <2,0 36 0,58 16,7(6,8-41,0) 
relapse >9.95 53,6 0,88 4,9(2,1-11,6) 
Table 3.8. TRAb cut-off levels for prediction of GD course at specificity level of 90% 
(remission), 81% (relapse). 
 
1 - specificity
1,00,80,60,40,20,0
se
ns
iti
vi
ty
1,0
0,8
0,6
0,4
0,2
0,0
 
Fig. 3.15. ROC curve for TRAb levels 6 months after onset of hyperthyroidism in 
relapse group.  
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3.5.9. Relation between course of GO and course of hyperthyroidism  
98 patients with the mild course of GO and 174 with the severe course were 
classified according to their thyroid status at the end of the study (Fig. 3.16. and 
3.17.). The mild course was related to euthyroidism (OR=5,46 [1,93-15,46]; 
p=0,0004) and a higher GD remission rate (OR=3,48 [1,93-6,25]; p<0,0001). 
The course of hyperthyroidism was related to both the CAS and NOSPECS 
values (p=0,006 and p<0,0001 respectively). HT was not related to the course 
of GO (p=0,783). 
 
 
 
Fig. 3.16. Thyroid status at end of study in patients with mild course of GO. In red 
percentage of patients that underwent ablative therapy of thyroid (n=114). 
RAI – Radioiodine treatment of the thyroid  
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Fig. 3.17. Thyroid status at end of study in patients with severe course of GO. In red 
percentage of patients that underwent ablative therapy of thyroid (n=184). 
RAI – Radioiodine treatment of thyroid  
 
3.6. Stepwise logistic regression on risk factors that influence course of 
hyperthyroidism 
A stepwise logistic regression was performed in order to test the association 
between the relapse rate of hyperthyroidism and the GNAS1 T393C SNP 
genotypes, the TRAb levels 6 months after the initiation of the ATD treatment, 
the age at the GD onset and smoking. A significance level of 0,1 was 
demanded for a given parameter to enter the model, and 0,2 to remain in it. 
The GNAS1 genotype marginally failed the significance (p=0,055); the odds 
ratio for having the C allele vs. having no C allele was 0,116 (95%CI [0,013-
1,051]) as long as the TRAb values 6 months after the beginning of the ATD 
therapy remained in the model (for TRAb: p=0,0024, odds ratio for one unit 
increase was 1,132 (95%CI [1,045-1,226]). Without TRAb in the model, the 
GNAS1 status (CC+CT vs. TT) and smoking became significant. The age 
stayed in the model, but did not reach the significance level at any point (Table 
3.9.). The gender did not stay in the model. 
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Factors that influence the course 
of hyperthyroidism 
p Odds ratio (95%CI) 
GNAS1 status  
CC+CT vs. TT 
0,019 0,209 (0,056-0,775) 
Smoking (yes/no) 0,013 2,961 (1,263-6,942) 
Age (years) 0,059 1,108 (0,996-1,233) 
for every 3 years 
Table 3.9. Results of logistic regression on risk factors that influence course of 
hyperthyroidism. 
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4. Discussion 
 
4.1. Patient characteristics 
The epidemiological parameters of our study group were compatible with those 
found in the literature. Our patients were recruited from a tertiary referral 
ophthalmology clinic, and thus included a high proportion of severe cases of 
GO, which have somewhat limited our research. 
 
According to Perros et al. the mean age at the onset is 46 years for GD with GO 
and 40 with GD alone (Perros et al. 1998). In our patients, the median age was 
slightly higher (47,9 years), which was related to the bigger number of severe 
cases. 52% of smokers in our group, as compared to 40% reported in the 
recent EUGOGO study (Prummel et al. 2003), can be explained in a similar 
way. 
Concerning the frequency of the eye symptoms, there was no difference in 
comparison to other tertiary referral centres (Bartley et al. 1996). The presence 
of GO can be interpreted as a more severe GD stage. Hence it is not surprising 
that the rate of hyperthyroidism remission was lower in our cohort, compared to 
a group of GD patients with less prevalent GO. The overall remission rate of 
such group is about 50% (Orgiazzi et al. 2002). With the presence of GO, the 
rate decreases to 21.6% (Vitti et al. 1997), similarly as in our cohort.  
The frequency of concomitant autoimmune diseases was comparable to others 
(Szyper-Kravitz et al. 2005). The family history was slightly less frequent, 
comparing to a recent study done in the UK (29% vs 47.4% of GD females, 
40.0% of GD males) (Manji et al. 2006).  
 
4.2. Genetic susceptibility of Graves’ disease (GD) and Graves’ 
orbitopathy (GO) 
There was no significant association between the development of GD or GO 
and the tested polymorphisms.  
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4.3. Influence of G protein genotypes and nongenetic parameters on course 
of GO 
 
4.3.1. G protein polymorphisms and course of GO 
The GNAS1 T393C and GNB3 C825T polymorphisms, and allele frequencies 
were related neither to the occurrence nor the course of GO. However, a 
significant relation between the more severe disease and absence of the C 
allele in the GNAS1 T393C gene was found in the thyroid disease. An 
analogical relation was expected in GO, since the severe stages of both GO 
and GD were significantly associated with the higher TRAb levels. According to 
Pritchard et al., IgGs of GO patients cause significant proliferation and 
inflammation in the orbital fibroblast cell cultures (Pritchard et al. 2002). One 
possible explanation could be the presence of GO in all patients. Unfortunately 
no patients with Graves’ disease without GO were available for further 
comparison.  
 
4.3.2. Nongenetic factors that influence course of GO 
According to Bartalena et al., gender, age, smoking and thyroid dysfunction are 
all related to GO (Bartalena et al. 1998). The last three were confirmed in our 
study, while the association with gender failed the significance marginally 
(p=0,068). Moreover, the thyroid volume and TRAb levels 6 months after the 
GO onset were identified as the risk factors for the severe course of GO 
(comparable to (Eckstein et al. 2006)). The cut-off levels for TRAb in 
association with the mild or severe course of GO could nearly be confirmed: 
75% of the patients with TRAb ≥11,2 IU/l presented severe GO, while 65% of 
the patients with TRAb <3,0 IU/l manifested the mild clinical course of the 
disease.  
Smoking generally increases the incidence and severity of GO and is the 
strongest modifiable risk factor for GO (Prummel et al. 1993). In the present 
study, 2,5-fold higher risk of severe GO was noted for smokers. According to 
Cawood et al. (2007), superoxide radicals, hypoxia, nicotine and tar influence 
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the orbital fibroblasts proliferation, GAGs production, and HLA II molecules 
expression (Cawood et al. 2007). 
 
4.4. Influence of G protein genotypes and nongenetic parameters on course 
of hyperthyroidism 
 
4.4.1. G protein polymorphisms and course of hyperthyroidism 
The genotype distribution of GNAS1 T393C SNP differed significantly in the 
remission and relapse GD patients (p=0,013). Particularly the homozygous TT 
carriers showed a much higher risk of relapse.  
 
The results gave rise to several questions:  
1. Are these random results?  
Random results are unlikely because the genotype distribution in our group was 
compatible with the Hardy-Weinberg equilibrium. It was also similar to the 
genotype distribution in the controls. 
  
2. What are the genetic and molecular mechanisms underlying these results? 
The C393T polymorphism, the T to C substitution at nucleotide position 393, is 
silent and does not change the coded aminoacid. However this polymorphism 
does not seem neutral. Firstly, it can change the folding structure of the 
messenger ribonucleic acid (mRNA), and consequently its expression. 
Secondly, the T393C SNP could be linked to another SNP,  which would modify 
the gene splicing and binding of the transcription factors. Bachmann (2006) 
examined the splice variants of different genotypes in the GNAS1 gene. He did 
not find any differences among the genotypes (Bachmann 2006) but he 
observed genotype dependent differences of the Gαs-mRNA expression in 
adipose tissue. It could be shown in vitro that quantitative variations of the Gαs 
expression influenced the efficacy of the signal transduction to the adenyl 
cyclase (Krumins et al. 1997). Thus linked SNP in the promoter region of the 
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gene was suggested. Sequencing the promoter region revealed two new SNPs, 
although not linked to T393C SNP.  
We assume there was increased signalling to TRAb in the patients with TT 
genotypes. The patients with the TT polymorphism of GNAS1 T393C had 
significantly higher TRAb levels and were more likely to relapse. In the stepwise 
logistic regression on the factors influencing the course of GD, GNAS1 T393C 
SNP lacked significance as long as the TRAb levels were included. The 
question whether only the increased levels of TRAb are responsible for the 
higher relapse rate, or the effect is significantly amplified by the TT genotype 
can therefore not be answered yet. 
 
Besides TSH-R, much of the recent interest centers on IGF-1-R. It is a widely 
expressed tyrosine kinase receptor abundantly found in connective tissue of GD 
and GO patients (Douglas et al. 2007). Its downstream signaling pathway 
results in the IL-16 and RANTES (Regulated on Activation Normal T-
lymphocyte Expressed and Secreted) expressions and consequently, leads to 
the T cell migration and lymphocyte infiltration of the thyroid gland as well as of 
the orbital connective tissue (Pritchard et al. 2003). The effects of RANTES are 
mediated by at least 4 G protein-coupled receptors (Pritchard et al. 2002), the 
signal transduction of which could be modulated by GNAS1 T393C SNP. 
However, the relevance of Gαs to the downstream signaling pathway of IGF-1-
R is indirect and not as clear as of TSH-R. 
  
Natural mutations in G proteins frequently result in human diseases. Defects in 
G proteins almost always lead to endocrine disorders. Nonetheless, so far only 
GNAS1 has been identified as unequivocally causing such disorders. The 
observation that Albright’s hereditary osteodystrophy (another disorder caused 
by a mutation of GNAS1) displays different phenotypes depending on the 
transmitting parent, leads to suspect that GNAS1 is an under tissue-specific 
imprinting control (Liu et al. 2000; Liu et al. 2005). Subsequently, evidence was 
provided that GNAS1 transcripts in the thyroid (as in other endocrine tissues, 
such as ovary and pituitary) are predominantly of a maternal origin (Liu et al. 
2005). It may be speculated that the (partial) maternal imprinting of the GNAS1 
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gene in the thyroid is related to the relatively favourable clinical course of GD in 
patients with the heterozygous TC genotype of T393C SNP.  
 
3. What is the clinical impact of the result? 
The GNAS1 genomic gene modifications are generally suited for prediction of 
risks and courses of diseases, including endocrine disorders (Weinstein et al. 
2001). Our research was the first to investigate the relevance of these 
polymorphisms to GD and GO. We found that GNAS1 T393C SNP was a minor 
disease modifying factor, and the TT allele, an independent risk factor for the 
hyperthyroidism relapse. 
It is tempting to presume that the influence of GNAS1 T393C SNP is stronger in 
average GD patients than in those from a tertiary referral centre. An ideal study 
sample should include an adequate number of patients in remission, ones with 
a mild course of GO, and also ones with no orbital involvement.  
 
4.4.2. Nongenetic factors that influence course of hyperthyroidism 
The present study confirms that the age of patients and thyroid volume 
influence the course of hyperthyroidism in GD as suggested by Orgiazzi J et al 
(Orgiazzi et al. 2002). However, the association with gender and smoking was 
not found.  The inconsistency regarding the influence of smoking on the course 
of GD might be attributed to the insufficient number of remission patients in our 
group. 
 
The relapse of hyperthyroidism after the discontinuation of the ATD therapy was 
related to high TRAb levels. Cut-off levels of TRAb 6 months after the beginning 
of the antithyroid drug therapy were comparable to the earlier studies (Schott et 
al. 2004). In our study, 81% of the patients with TRAb levels ≥9,95 IU/l 6 
months after the beginning of the ATD therapy relapsed. The relapse rate was 
slightly lower in comparison to the study of Schott et al., where 97% of the 
patients relapsed by the TRAb cut-off levels of ≥10,0 IU/l (Schott et al. 2004). 
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4.5. Relation between course of GO and GD 
The presence of GO is considered the risk factor for the relapse of 
hyperthyroidism after the cessation of ATD (reviewed in: (Orgiazzi et al. 2002)). 
In a large retrospective trial, Vitti et al. (1997) reported the higher risk of the 
hyperthyroidism relapse in patients with GO (71.9%) than in those without GO 
(57.8%) (Vitti et al. 1997). Furthermore, the more severe course of GO, the 
higher rate of hyperthyroidism relapse. In our cohort, only 14% of the patients 
with a severe course remained in stable hyperthyroidism remission, as opposed 
to 37% with a mild GO. Many studies have shown that the severity of both GO 
and GD is closely related to the TRAb levels. In addition both diseases (GO and 
GD) share such risk factors as smoking, male gender, large goiter, 
hypoechogenic and hypervascular gland (Perros et al. 1993; Vitti et al. 1997; 
Bartalena et al. 1998; Orgiazzi et al. 2002) 
Hence, the severity of GO indicates a certain risk for the severity of 
hyperthyroidism and vice versa (summarized in: (Eckstein et al. 2009)). In 
practical terms, the patients with severe GO and high TRAb levels face a much 
higher risk for relapse of hyperthyroidism than those with low TRAb levels and 
mild GO. In a previous study we reported, based on the stepwise logistic 
regression analysis, on the following parameters influencing the course of 
hyperthyroidism: course of GO, TRAb levels, age, gender and smoking 
(Eckstein et al. 2007). Most of the factors were confirmed in this study. 
Additionally, increased thyroid volume was related to both the severe course of 
GO and relapse of hyperthyroidism. 
.  
In clinical practice, the present study should encourage a faster decision for the 
definitive treatment of the thyroid, at least in those countries where prolonged 
and repeated ATD is still the first choice therapy (e.g. in Europe and Japan). 
Decisions based on the TRAb levels are possible as early as 6 months after the 
beginning of the ATD treatment. 12 months after the GO onset the decisions 
can be made according to the activity and severity scores of GO and again, the 
TRAb levels. 
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Future studies should prove whether the early definitive treatment of the thyroid 
dysfunction in high risk patients can improve the course of GO. The early 
definitive treatment of the thyroid in the patients most affected by the disease 
may at least shorten the period of fluctuation in the thyroid function and allow 
earlier surgical rehabilitation of the orbit. 
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5. Zusammenfassung  
Die Biologie der Initiation und Progression von Morbus Basedow-Krankheit und 
der Endokriner Orbitopathie ist komplex. Für eine individuell angepasste 
Therapie der Schilddrüsenüberfunktion und der Orbitopathie ist die Kenntnis 
von Risikofaktoren die mit einem milden bzw. schweren Verlauf der 
Schilddrüsen- bzw. Augenerkrankung assoziiert sind wichtig. Hohe Spiegel der 
Anti-TSH-Rezeptor-Antikörper gemessen zu bestimmten Zeitpunkten im Verlauf 
der Schilddrüsen- und Augenerkrankung erlauben eine Risikobeurteilung.  
Die Signaltransduktion des TSH-Rezeptors erfolgt über das G-Protein. Ziel der 
Arbeit war herauszufinden ob zwei Einzelnukleotid-Polymorphismen in der Gαs 
und Gß3 Untereinheit des G-Proteins den Verlauf der Basedow Erkrakung 
beeinflussen.  
In einer Serie von 359 Patienten haben wir Genotyp und Allelfrequenzen der 
Einzelnukleotid-Polymorphismen GNAS1 T393C und GNB3 C825T untersucht. 
Sie tragen nicht zur individuellen Anfälligkeit gegenüber der  Morbus Basedow-
Krankheit und der Endokrinen Orbitopathie bei. Doch der TT-Genotyp des 
GNAS1 T393C Gens ist mit einem signifikant erhöhten Risiko eines Rezidivs 
der Hyperthyreose verbunden (Odds Ratio 2,5; 95%-Konfidenzintervalle: 1,1; 
5,5; p=0,025). Die zugrunde liegenden molekularen Mechanismen sind nicht 
leicht zu erklären. Eine der Hypothesen ist eine Änderung in der 
Sekundärstruktur der mRNA durch den Polymorphismus, die die Stabilität 
beeinflussen könnte. Klinisch waren die Anti-TSH-Rezeptor-Antikörper Spiegel 
in der Patientengruppe mit dem TT-Genotyp am höchsten. Aus diesem Grund 
kann die Frage, ob nur erhöhte TSH-Rezeptor-Antikörper bei Patienten mit dem 
TT-Genotyp für die höheren Rezidivraten verantwortlich sind oder ob dieser 
Effekt signifikant vom TT-Genotyp verstärkt wird, anhand der untersuchten 
Patientenkohorte nicht beantwortet werden. Aus diesem Grund muss die 
Kohorte noch erweitert werden, um herauszufinden ob die Genotypisierung des 
T393C Einzelnukleotid-Polymorphismus des GNAS1 Gens eine nützliche 
zusätzliche Untersuchung ist, um den klinischen Verlauf der Basedow-Krankheit 
vorherzusagen. 
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6. Summary 
The biology of initiation and progression of Graves’ hyperthyroidism and 
Graves’ orbitopathy is complex. For the individually tailored therapy of the 
diseases it is very important to identify the risk factors. Research of the last 
century revealed that measuring the thyrotropin receptor antibody levels 
enables the prognostic statements at certain points in the course of 
hyperthyroidism and orbitopathy. Signal transduction of the thyrotropin receptor 
is coupled with G protein. The aim of the present study was to find out if two 
single nucleotide polymorphisms that encode the Gαs and Gβ3 subunits of G 
protein were related to the course of Graves’ disease.  
In a series of 359 patients, the genotype and allele frequencies of the GNAS1 
T393C and GNB3 C825T single nucleotide polymorphisms were determined. 
They did not contribute to the individual susceptibility to Graves’ 
hyperthyroidism and orbitopathy. However, the TT genotype of the GNAS1 
T393C gene was associated with a significantly increased risk of relapse of 
hyperthyroidism (odds ratio 2,5; 95% confidence interval 1,1-5,5; p=0,025).  
The underlying molecular mechanisms are not easy to explain. According to 
one of the hypotheses, changing a secondary structure of the mRNA influences 
its stability. Clinically, the thyrotropin receptor antibody levels are the highest in 
patients with the TT genotype. The question whether only the elevated antibody 
levels are responsible for the more severe course of hyperthyroidism or if this 
relation is supported by the TT genotype cannot be answered based on our 
study group. The studied cohort should be extended in order to find out if 
genotyping the T393C single nucleotide polymorphism of the GNAS1 gene is 
relevant for clinical decisions in the treatment of Graves’ hyperthyroidism.  
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8. Abbreviations 
cAMP cyclic adenosine monophosphate 
AITD autoimmune thyroid disease  
ATD antithyroid drug treatment  
CAS Clinical Activity Score  
cDNA  complementary deoxyribonucleic acid  
CT  computer tomography 
CTLA-4 cytotoxic T lymphocyte-associated antigen 4   
DNA deoxyribonucleic acid 
GAG glycosaminoglycans  
GD Graves’ disease  
GDP guanosine diphosphate  
GTP guanosine triphosphate  
GO Graves’ orbitopathy 
HLA human leukocyte antigen 
HT Hashimoto’s thyroiditis  
IFN-γ  interferon-γ 
IGF-1-R insulin-like growth factor-1 receptor  
IL-1 interleukin-1  
IU/l international units per liter 
MHCII major histocompatibility complex II  
MRI magnetic resonance imaging 
mRNA messenger ribonucleic acid  
OR odds ratio 
PCR polymerase chain reaction 
RAI radioiodine  
RANTES  
Regulated on Activation Normal T-lymphocyte Expressed and 
Secreted 
SD standard deviation 
SNP single nucleotide polymorphism  
TBAb TSH-R blocking antibodies  
TBII thyrotropin-binding inhibitory immunoglobulin  
Tc T cytotoxic lymphocyte 
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Tg thyroglobulin  
Th T helper lymphocyte 
TNF tumor necrosis factor 
TPO thyroid peroxidase  
Ts T suppressive lymphocyte 
TSAb TSH-R stimulating antibodies 
TSH thyrotropin  
TSH-R thyrotropin receptor 
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